Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy.

dc.contributor.authors	Bangalore S, Messerli FH, Cohen JD, Bacher PH, Sleight P, Mancia G, Kowey P, Zhou Q, Champion A, Pepine CJ; INVEST Investigators.
dc.date.accessioned	2020-02-27T08:30:43Z
dc.date.available	2020-02-27T08:30:43Z
dc.date.issued	2008
dc.identifier.citation	Bangalore S, Messerli FH, Cohen JD, Bacher PH, Sleight P, Mancia G, Kowey P, Zhou Q, Champion A, Pepine CJ; INVEST Investigators. (2008). Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy.. AMERICAN HEART JOURNAL, 156, 247-241
dc.identifier.issn	0002-8703
dc.identifier.uri	https://doi.org/10.1016/j.ahj.2008.02.023
dc.identifier.uri	https://hdl.handle.net/20.500.12619/66231
dc.title	Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy.
dc.identifier.volume	156
dc.identifier.startpage	241
dc.identifier.endpage	247
dc.contributor.department	Sakarya Üniversitesi/Tıp Fakültesi/Dahili Tıp Bilimleri Bölümü
dc.contributor.saüauthor	Akdemir, Ramazan
dc.relation.journal	AMERICAN HEART JOURNAL
dc.identifier.wos	SAU
dc.identifier.doi	10.1016/j.ahj.2008.02.023
dc.contributor.author	Akdemir, Ramazan